Evonik offers Tessenderlo customers secure supply of glycine
Essen, Germany-based Evonik Industries has assumed ownership of the customer list for the pharmaceutical amino acid glycine of the Tessenderlo Group of Brussels (Belgium). By the end of the year, Tessenderlo will withdraw from the glycine business completely and close its own production plant in Belgium. Evonik’s product line Rexim produces the pharmaceutical amino acid based on the strict specifications of the cGMP (current Good Manufacturing Practice) at its site in Wuming (China), where it is currently expanding capacities.
Through intensive research in the field of white biotechnology, Evonik has continuously expanded its portfolio of pharmaceutical-grade amino acids in recent years. ““Offering Tessenderlo’s customers a sustainable supply of high-quality glycine is one more step in consolidating our pharmaceutical amino acid business,” says Dr. Thomas Hermann, head of the Rexim Product Line, a subsidiary of Evonik’s Health & Nutrition Business Unit.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Next-generation perovskite solar cells made stable by metal oxide “sandwich” - Perovskite solar cells with metal oxide hole and electron transport layers
Overlack Group strengthens its Europe-wide network with the acquisition of Ceepal
Anti-nuclear_antibody
Whatman GD/X™ syringe filters | Syringe filters | Cytiva
Carbon nanotubes grow in combustion flames
Ralph R. Dammel from Merck receives the Frits Zernike Award for Microlithography
Degussa Receives Approval from Chinese Au-thorities to Build Integrated Methacrylates Production Facility
Sartorius Concludes Agreement to Acquire the Liquid Handling Business of the Laboratory Supplier Biohit - Sales and purchase agreement signed for 68 million euros
Category:Heterocyclic_compounds_(bridged-ring)
Nutraceutical Products Targeting Weight Management to Garner Revenues in Southeast Asia
